Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07038876 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

A Phase 2 study of Schizophrenia, sponsored by MapLight Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
300
Enrollment target
20
Study locations

NCT07038876 is a Phase 2 study of Schizophrenia that is actively recruiting participants, run by MapLight Therapeutics. The registered enrollment target is 300 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07038876, a Phase 2 study of Schizophrenia, is actively recruiting participants, sponsored by MapLight Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.

Conditions Studied

Schizophrenia

Interventions

  • DRUG Placebo
  • DRUG ML-007C-MA BID
  • DRUG ML-007C-MA QD

Study Locations (20)

California

  • Clinical Site - Bellflower
  • Clinical Site - Culver City
  • Clinical Site - Garden Grove
  • Clinical Site - Lemon Grove
  • Clinical Site - Los Angeles
  • Clinical Site - Montclair
  • Clinical Site - Orange
  • Clinical Site - Riverside
  • Clinical Site - San Diego
  • Clinical Site - Santee
  • Clinical Site - Sherman Oaks
  • Clinical Site - Torrance

Florida

  • Clinical Site - Hollywood
  • Clinical Site - Miami Lakes
  • Clinical Site - West Palm Beach

Georgia

  • Clinical Site - Atlanta
  • Clinical Site - Decatur

Arkansas

  • Clinical Site - Little Rock

Illinois

  • Clinical Site - Chicago

New Jersey

  • Clinical Site - Marlton

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2025-06-27
Est. Completion 2026-08
Phase Phase 2

Sponsor

MapLight Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07038876

The ClinicalTrials.gov registry entry for NCT07038876 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (38% higher). The listed sponsor is MapLight Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT07038876 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT07038876 about?

NCT07038876 is a clinical study titled "A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia". ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary ob...

What is the current status of trial NCT07038876?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2025-06-27. Estimated completion is 2026-08.

What conditions does trial NCT07038876 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT07038876?

The interventions under investigation include: Placebo (DRUG), ML-007C-MA BID (DRUG), ML-007C-MA QD (DRUG).

Who is sponsoring clinical trial NCT07038876?

This trial is sponsored by MapLight Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07038876 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.